No significant association was found between EGFR mutation and OS of patients, even considering early stages I. These data were not in line with other previous published works, where a clear strong association of pathological stage I resected NSCLC patients with longer OS and progression-free survival (PFS) was reported [33]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.